Full text biomedical articles

Variation in the UGT2B17 genotype, exemestane metabolism and menopause-related toxicities in the CCTG MAP.3 trial

Vikki Ho, Romain Pasquet, Shaman Luo, Gang Chen, Paul Goss, Dongsheng Tu, Philip Lazarus, Harriet Richardson
Breast Cancer Res Treat. Author manuscript; available in PMC 2021 Oct 1.
Published in final edited form as: Breast Cancer Res Treat. 2020 Oct; 183(3): 705–716. Published online 2020 Aug 1. doi: 10.1007/s10549-020-05812-1


Article   |   PubReader   |   PDF–463K   |   Cite

Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 12 weeks' exemestane exposure in patients with estrogen receptor‐positive breast cancer: A multicenter, open‐label, phase II study

Nobuaki Sato, Norikazu Masuda, Takashi Morimoto, Takayuki Ueno, Chizuko Kanbayashi, Koji Kaneko, Hiroyuki Yasojima, Shigehira Saji, Hironobu Sasano, Satoshi Morita, Shinji Ohno, Masakazu Toi
Cancer Med. 2019 Sep; 8(12): 5468–5481. Published online 2019 Jul 30. doi: 10.1002/cam4.2423


Article   |   PubReader   |   PDF–574K   |   Cite

Exemestane blocks mesothelioma growth through downregulation of cAMP, pCREB and CD44 implicating new treatment option in patients affected by this disease

Barbara Nuvoli, Sabrina Germoni, Carlotta Morosetti, Raffaela Santoro, Giancarlo Cortese, Serena Masi, Iole Cordone, Rossella Galati
Mol Cancer. 2014; 13: 69. Published online 2014 Mar 21. doi: 10.1186/1476-4598-13-69


Article   |   PubReader   |   PDF–1.2M   |   Cite

Everolimus Plus Exemestane for the Treatment of Advanced Breast Cancer: A Review of Subanalyses from BOLERO-2

Gabriel N. Hortobagyi
Neoplasia. 2015 Mar; 17(3): 279–288. Published online 2015 Mar 23. doi: 10.1016/j.neo.2015.01.005


Article   |   PubReader   |   PDF–290K   |   Cite

Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in post-menopausal patients with breast cancer

Daniel L. Hertz, Kelley M. Kidwell, Nicholas J. Seewald, Christina L. Gersch, Zeruesenay Desta, David A Flockhart, Ana-Maria Storniolo, Vered Stearns, Todd C Skaar, Daniel F Hayes, N. Lynn Henry, James M. Rae
Pharmacogenomics J. Author manuscript; available in PMC 2017 Nov 30.
Published in final edited form as: Pharmacogenomics J. 2017 Dec; 17(6): 521–527. Published online 2016 Aug 23. doi: 10.1038/tpj.2016.60


Article   |   PubReader   |   PDF–709K   |   Cite

Preclinical evaluation of exemestane as a novel chemotherapy for gastric cancer

Juan‐Cheng Yang, Ning Chang, Deng‐Chyang Wu, Wei‐Chung Cheng, Wei‐Min Chung, Wei‐Chun Chang, Fu‐Ju Lei, Chung‐Jung Liu, I‐Chen Wu, Hsueh‐Chou Lai, Wen‐Lung Ma
J Cell Mol Med. 2019 Nov; 23(11): 7417–7426. Published online 2019 Sep 26. doi: 10.1111/jcmm.14605


Article   |   PubReader   |   PDF–1.2M   |   Cite

Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor–Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy

Meritxell Bellet, Kathryn P. Gray, Prudence A. Francis, István Láng, Eva Ciruelos, Ana Lluch, Miguel Angel Climent, Gustavo Catalán, Antoni Avella, Uriel Bohn, Antonio González-Martin, Roser Ferrer, Roberto Catalán, Analía Azaro, Agnita Rajasekaran, Josefa Morales, Josep Vázquez, Gini F. Fleming, Karen N. Price, Meredith M. Regan
J Clin Oncol. 2016 May 10; 34(14): 1584–1593. Published online 2016 Jan 4. doi: 10.1200/JCO.2015.61.2259


Article   |   PubReader   |   PDF–1.4M   |   Cite

Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor–Positive, HER2-Negative Advanced Breast Cancer: The BOLERO-6 Randomized Clinical Trial

Guy Jerusalem, Richard H. de Boer, Sara Hurvitz, Denise A. Yardley, Elena Kovalenko, Bent Ejlertsen, Sibel Blau, Mustafa Özgüroğlu, László Landherr, Marianne Ewertz, Tetiana Taran, Jenna Fan, Florence Noel-Baron, Anne-Laure Louveau, Howard Burris
JAMA Oncol. 2018 Oct; 4(10) Published online 2018 Jun 3. doi: 10.1001/jamaoncol.2018.2262


Article   |   PubReader   |   Cite

Impact of the OATP1B1 c.521T>C Single Nucleotide Polymorphism on the Pharmacokinetics of Exemestane in Healthy Postmenopausal Female Volunteers

Bryana J. Gregory, Shanly M. Chen, Michael A. Murphy, Daniel H. Atchley, Landry K. Kamdem
J Clin Pharm Ther. Author manuscript; available in PMC 2018 Oct 1.
Published in final edited form as: J Clin Pharm Ther. 2017 Oct; 42(5): 547–553. Published online 2017 Jul 29. doi: 10.1111/jcpt.12569


Article   |   PubReader   |   PDF–779K   |   Cite

Quality of Life in MAP.3 (Mammary Prevention 3): A Randomized, Placebo-Controlled Trial Evaluating Exemestane for Prevention of Breast Cancer

Elizabeth Maunsell, Paul E. Goss, Rowan T. Chlebowski, James N. Ingle, José E. Alés-Martínez, Gloria E. Sarto, Carol J. Fabian, Pascal Pujol, Amparao Ruiz, Andrew L. Cooke, Susan Hendrix, Debra W. Thayer, Kendrith M. Rowland, Pierre Dubé, Silvana Spadafora, Sandhya Pruthi, Lavina Lickley, Susan L. Ellard, Angela M. Cheung, Jean Wactawski-Wende, Karen A. Gelmon, Dianne Johnston, Andrea Hiltz, Michael Brundage, Joseph L. Pater, Dongsheng Tu, Harriet Richardson
J Clin Oncol. 2014 May 10; 32(14): 1427–1436. Published online 2014 Apr 7. doi: 10.1200/JCO.2013.51.2483


Article   |   PubReader   |   PDF–245K   |   Cite

Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer

P. A. Francis, O. Pagani, G. F. Fleming, B. A. Walley, M. Colleoni, I. Láng, H. L. Gómez, C. Tondini, E. Ciruelos, H. J. Burstein, H. R. Bonnefoi, M. Bellet, S. Martino, C. E. Geyer, M. P. Goetz, V. Stearns, G. Pinotti, F. Puglisi, S. Spazzapan, M. A Climent, L. Pavesi, T. Ruhstaller, N. E. Davidson, R. Coleman, M. Debled, S. Buchholz, J. N. Ingle, E. P. Winer, R. Maibach, M. Rabaglio‑Poretti, B. Ruepp, A. Di Leo, A. S. Coates, R. D. Gelber, A. Goldhirsch, M.M. Regan, for the SOFT and TEXT Investigators and the International Breast Cancer Study Group
N Engl J Med. Author manuscript; available in PMC 2019 Jan 12.
Published in final edited form as: N Engl J Med. 2018 Jul 12; 379(2): 122–137. Published online 2018 Jun 4. doi: 10.1056/NEJMoa1803164


Article   |   PubReader   |   PDF–2.2M   |   Cite

Endocrine therapies in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative, pretreated, advanced breast cancer: A network meta-analysis

Cho-Hao Lee, Yi-No Kang, Ching-Liang Ho, Chin Lin, Po-Huang Chen, Yi-Ying Wu, Tzu-Chuan Huang
Medicine (Baltimore) 2020 Mar; 99(13): e19618. Published online 2020 Mar 27. doi: 10.1097/MD.0000000000019618


Article   |   PubReader   |   PDF–2.8M   |   Cite

Initiation of sex change and gonadal gene expression in black sea bass (Centropristis striata) exposed to exemestane, an aromatase inhibitor

Timothy S. Breton, Linas W. Kenter, Katherine Greenlaw, Jacob Montgomery, Giles W. Goetz, David L. Berlinsky, J. Adam Luckenbach
Comp Biochem Physiol A Mol Integr Physiol. Author manuscript; available in PMC 2020 Feb 1.
Published in final edited form as: Comp Biochem Physiol A Mol Integr Physiol. 2019 Feb; 228: 51–61. Published online 2018 Nov 9. doi: 10.1016/j.cbpa.2018.10.024


Article   |   PubReader   |   PDF–1.0M   |   Cite

Exemestane use in postmenopausal women at high risk for invasive breast cancer: evaluating biomarkers of efficacy and safety

Margaret Gatti-Mays, David Venzon, Claudia Galbo, Andrea Singer, James Reynolds, Erini Makariou, Bhaskar Kallakury, Brandy Heckman-Stoddard, Larissa Korde, Claudine Isaacs, Robert Warren, Ann Gallagher, Jennifer Eng-Wong
Cancer Prev Res (Phila) Author manuscript; available in PMC 2017 Mar 1.
Published in final edited form as: Cancer Prev Res (Phila). 2016 Mar; 9(3): 225–233. Published online 2016 Jan 12. doi: 10.1158/1940-6207.CAPR-15-0269


Article   |   PubReader   |   PDF–1.0M   |   Cite

Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor‐positive, human epidermal growth factor receptor 2‐negative locally advanced or metastatic breast cancer: Results of the single‐arm, phase IIIB 4EVER trial

Hans Tesch, Oliver Stoetzer, Thomas Decker, Christian M. Kurbacher, Frederik Marmé, Andreas Schneeweiss, Christoph Mundhenke, Andrea Distelrath, Peter A. Fasching, Michael P. Lux, Diana Lüftner, Peyman Hadji, Wolfgang Janni, Mathias Muth, Julia Kreuzeder, Claudia Quiering, Florin‐Andrei Taran
Int J Cancer. 2019 Feb 15; 144(4): 877–885. Published online 2018 Oct 30. doi: 10.1002/ijc.31738


Article   |   PubReader   |   PDF–661K   |   Cite

A Computational Approach with Biological Evaluation: Combinatorial Treatment of Curcumin and Exemestane Synergistically Regulates DDX3 Expression in Cancer Cell Lines

Shailima Rampogu, Seong Min Kim, Minky Son, Ayoung Baek, Chanin Park, Gihwan Lee, Yumi Kim, Gon Sup Kim, Ju Hyun Kim, Keun Woo Lee
Biomolecules. 2020 Jun; 10(6): 857. Published online 2020 Jun 4. doi: 10.3390/biom10060857


Article   |   PubReader   |   PDF–5.8M   |   Cite

Methylome Variation Predicts Exemestane Resistance in Advanced ER+ Breast Cancer

Xiao-ran Liu, Ru-yan Zhang, Hao Gong, Hope S. Rugo, Ling-bo Chen, Yuan Fu, Jian-wei Che, Jian Tie, Bin Shao, Feng-ling Wan, Wei-yao Kong, Guo-hong Song, Han-fang Jiang, Guo-bing Xu, Hui-ping Li
Technol Cancer Res Treat. 2020; 19: 1533033819896331. Published online 2020 Mar 4. doi: 10.1177/1533033819896331


Article   |   PubReader   |   PDF–968K   |   Cite

Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer

Jason D. Robarge, Zereunesay Desta, Anne T. Nguyen, Lang Li, Daniel Hertz, James. M. Rae, Daniel F. Hayes, Anna M. Storniolo, Vered Stearns, David A. Flockhart, Todd C. Skaar, N. Lynn Henry
Breast Cancer Res Treat. Author manuscript; available in PMC 2018 Feb 1.
Published in final edited form as: Breast Cancer Res Treat. 2017 Feb; 161(3): 453–461. Published online 2016 Dec 9. doi: 10.1007/s10549-016-4077-4


Article   |   PubReader   |   PDF–778K   |   Cite

New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane

STINE HOLE, ASTRID M. PEDERSEN, SUSANNE K. HANSEN, JOHAN LUNDQVIST, CHRISTINA W. YDE, ANNE E. LYKKESFELDT
Int J Oncol. 2015 Apr; 46(4): 1481–1490. Published online 2015 Jan 26. doi: 10.3892/ijo.2015.2850


Article   |   PubReader   |   PDF–723K   |   Cite

Impact of UGT2B17 Gene Deletion on the Pharmacokinetics of 17-hydroexemestane in Healthy Volunteers

Shanly M. Chen, Daniel H. Atchley, Michael A. Murphy, Bill J. Gurley, Landry K. Kamdem
J Clin Pharmacol. Author manuscript; available in PMC 2017 Jul 1.
Published in final edited form as: J Clin Pharmacol. 2016 Jul; 56(7): 875–884. Published online 2015 Dec 31. doi: 10.1002/jcph.673


Article   |   PubReader   |   PDF–437K   |   Cite